Torin 1

Catalog No.S2827

Torin 1 is a potent inhibitor of mTORC1/2 with IC50 of 2 nM/10 nM in cell-free assays; exhibits 1000-fold selectivity for mTOR than PI3K.

Price Stock Quantity  
USD 170 In stock
USD 370 In stock
USD 670 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Torin 1 Chemical Structure

Torin 1 Chemical Structure
Molecular Weight: 607.62

Validation & Quality Control

4 customer reviews :

Quality Control & MSDS

Related Compound Libraries

mTOR Inhibitors with Unique Features

Product Information

  • Compare mTOR Inhibitors
    Compare mTOR Products
  • Research Area
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Torin 1 is a potent inhibitor of mTORC1/2 with IC50 of 2 nM/10 nM in cell-free assays; exhibits 1000-fold selectivity for mTOR than PI3K.
Targets mTORC1 [1]
(Cell-free assay)
mTOR [2]
(Cell-free assay)
DNA-PK [2]
(Cell-free assay)
mTORC2 [1]
(Cell-free assay)

 View  More

IC50 2 nM 4.32 nM 6.34 nM 10 nM
In vitro Torin1 inhibits phosphorylation of mTORC1 and mTORC2 substrates in cells at concentrations of 2 and 10 nM, respectively. Moreover, Torin1 exhibits 1000-fold selectivity for mTOR over PI3K (EC50 = 1800 nM) and exhibits 100-fold binding selectivity relative to 450 other protein kinases. [1] [2] Torin1 causes cell cycle arrest through a rapamycin-resistant mechanism that is also independent of mTORC2. Torin1 disrupts mTORC1-dependent phenotypes more completely than rapamycin. Rapamycin-resistant functions of mTORC1 are required for cap-dependent translation. [1] In a recent study, it is reported Torin1 increases neurotensin secretion and gene expression through activation of the MEK/ERK/c-Jun pathway in the human endocrine cell line BON. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
ETK-1MonKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYDJR|UxRTBwMECwN|A3KM7:TR?=M1rSdXNCVkeHUh?=
OCUB-MM4G4cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4PybWlEPTB;MD6wNFE6PCEQvF2=M2jNTHNCVkeHUh?=
DOHH-2NGXofVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHPxWoNKSzVyPUCuNFAzOjVizszNNHrwSnpUSU6JRWK=
NOS-1NILKUJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUTTOJRWUUN3ME2wMlAxOjR{IN88US=>NULPVYZoW0GQR1XS
L-363MkfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUjJR|UxRTBwMECyPFQh|ryPNH7zZWJUSU6JRWK=
RL95-2MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1z6T2lEPTB;MD6wNFMzKM7:TR?=MVHTRW5ITVJ?
BL-70M1rI[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUfJR|UxRTBwMECzN|ch|ryPNEPRUJhUSU6JRWK=
TGBC1TKBNILTTW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYPCfIgxUUN3ME2wMlAxOzd7IN88US=>MnXvV2FPT0WU
697M2fTVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFGwc3BKSzVyPUCuNFA3OzRizszNNIHIOHZUSU6JRWK=
RPMI-8226NEK1SJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVrJR|UxRTBwMEC2OVEh|ryPNXq3dJoyW0GQR1XS
BL-41M1fnZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUfZOFdrUUN3ME2wMlAxPjl4IN88US=>NEHEc4xUSU6JRWK=
MRK-nu-1NFSwXXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVXydJdrUUN3ME2wMlAxPzB5IN88US=>MUnTRW5ITVJ?
EW-1MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1S3XmlEPTB;MD6wNFc1QSEQvF2=MYrTRW5ITVJ?
EVSA-TNWrxdIhCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVzJR|UxRTBwMEC4PVIh|ryPMnuwV2FPT0WU
HUTU-80MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn7sTWM2OD1yLkCwPVI6KM7:TR?=NFu3Z|RUSU6JRWK=
VA-ES-BJNF[xUGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIPsfGNKSzVyPUCuNFA6QDRizszNMkPaV2FPT0WU
GCIYMm\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mo\XTWM2OD1yLkCxNFA4KM7:TR?=MUjTRW5ITVJ?
ES6MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUG2NVF2UUN3ME2wMlAyODh|IN88US=>M{jzW3NCVkeHUh?=
NALM-6NWn6cWNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFz1UYVKSzVyPUCuNFEyODJizszNMV;TRW5ITVJ?
LB996-RCCNF;sZnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlLJTWM2OD1yLkCxNVM4KM7:TR?=NEXkXYdUSU6JRWK=
EW-16NULEUJRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGjEOG5KSzVyPUCuNFEyQTJizszNMVTTRW5ITVJ?
KALS-1MoXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIDVbIVKSzVyPUCuNFEyQThizszNNHjvXYNUSU6JRWK=
OPM-2MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVzJR|UxRTBwMEGyPUDPxE1?MnT4V2FPT0WU
KU812NXexWHJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkTpTWM2OD1yLkCxNlk3KM7:TR?=NVLUemYzW0GQR1XS
A4-FukNF\TN|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlvQTWM2OD1yLkCxN|E6KM7:TR?=MV\TRW5ITVJ?
KGNM3[1Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NI\hbVJKSzVyPUCuNFE{PTlizszNMXLTRW5ITVJ?
KS-1NUOxNHg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXjJR|UxRTBwMEGzPVIh|ryPMnO4V2FPT0WU
no-11M1X6fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVHJR|UxRTBwMEGzPVUh|ryPM4fubXNCVkeHUh?=
PSN1NWf0dFYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFL1VlJKSzVyPUCuNFE1ODlizszNNGTEemRUSU6JRWK=
SK-LMS-1M2PqV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGPUcJFKSzVyPUCuNFE1OTNizszNMVjTRW5ITVJ?
LS-411NNWP0fIsyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUjMRW9HUUN3ME2wMlAyPDN7IN88US=>M4e3N3NCVkeHUh?=
HT-144NVHQZZRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmDVTWM2OD1yLkCxOFUyKM7:TR?=MWXTRW5ITVJ?
ACNNHric2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkL6TWM2OD1yLkCxOUDPxE1?MWjTRW5ITVJ?
RKOM3H2WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV3jUohLUUN3ME2wMlAyPTN|IN88US=>MVTTRW5ITVJ?
CMKMoX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3uyNWlEPTB;MD6wNVU1OyEQvF2=MWnTRW5ITVJ?
GB-1NVTYTVVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX7wWINLUUN3ME2wMlAyPTV|IN88US=>NIHJdIZUSU6JRWK=
KE-37MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Moe2TWM2OD1yLkCxOVc{KM7:TR?=M1\PO3NCVkeHUh?=
no-10NGCwW4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1mzUWlEPTB;MD6wNVU5PCEQvF2=M{DEUnNCVkeHUh?=
MOLT-16M2O3PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFG2dJZKSzVyPUCuNFE3OjJizszNNVLyWodsW0GQR1XS
HELNU\ScoFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHXHWHRKSzVyPUCuNFE3PCEQvF2=NIDYXWhUSU6JRWK=
NCI-H1355NWfBepZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnPZTWM2OD1yLkCxOlQ3KM7:TR?=M1y3dHNCVkeHUh?=
IST-MEL1NYDYOpF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUDJR|UxRTBwMEG3O|Qh|ryPNWPmc2w1W0GQR1XS
MHH-PREB-1MnPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4T3N2lEPTB;MD6wNVgyQCEQvF2=MV\TRW5ITVJ?
ES8M3LzSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mme3TWM2OD1yLkCxPFQ1KM7:TR?=Mn;SV2FPT0WU
LC-2-adM4q1RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF\UUopKSzVyPUCuNFIyOzdizszNNYnhUlJ2W0GQR1XS
LAMA-84M2DuNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoPrTWM2OD1yLkCyNVY4KM7:TR?=MljCV2FPT0WU
BV-173MnfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NW[y[mdLUUN3ME2wMlAzOjB|IN88US=>NUfBWVV[W0GQR1XS
SW872MnHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYPGXItZUUN3ME2wMlAzOjR5IN88US=>NUnrWHB3W0GQR1XS
SK-UT-1NU\PeGx4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWfJR|UxRTBwMEKyOlEh|ryPNHP0UWtUSU6JRWK=
OS-RC-2MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVvJR|UxRTBwMEKzNlMh|ryPMWfTRW5ITVJ?
NCI-H747MoLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYjJR|UxRTBwMEKzN{DPxE1?MlKxV2FPT0WU
MZ2-MELM2fwc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEWwb3BKSzVyPUCuNFI{OzdizszNMYPTRW5ITVJ?
TE-11NETNXJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3XQdmlEPTB;MD6wNlM4OiEQvF2=NFXaXGNUSU6JRWK=
KURAMOCHINGfSUFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFTqdmlKSzVyPUCuNFI1OTRizszNM{[0eHNCVkeHUh?=
HD-MY-ZMXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUXxOmhYUUN3ME2wMlAzPDJ4IN88US=>NVfuSmVGW0GQR1XS
GI-1NFnkW5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUjJR|UxRTBwMEK0Olkh|ryPMWnTRW5ITVJ?
LB1047-RCCM3q3[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGi1NlBKSzVyPUCuNFI1QDhizszNNVnLNmtMW0GQR1XS
TE-12MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH;QWHRKSzVyPUCuNFI2PSEQvF2=MXrTRW5ITVJ?
MZ7-melMkH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIXHfY5KSzVyPUCuNFI3ODlizszNM{\6UHNCVkeHUh?=
MMAC-SFNGTJZ3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWLJR|UxRTBwMEK2N|Mh|ryPNYTnZo1xW0GQR1XS
A101DNGrrSlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{P6[GlEPTB;MD6wNlY2KM7:TR?=M2G3UXNCVkeHUh?=
GR-STNULpbnN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MojOTWM2OD1yLkCyOlU2KM7:TR?=MkLLV2FPT0WU
MC116NH7NTmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEDzcndKSzVyPUCuNFI3QCEQvF2=MVTTRW5ITVJ?
Ramos-2G6-4C10M4DGSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3S1[2lEPTB;MD6wNlc2KM7:TR?=MlXjV2FPT0WU
ATN-1MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIK1bWNKSzVyPUCuNFI4QDlizszNMkP5V2FPT0WU
MFH-inoNIqzN21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3LWOmlEPTB;MD6wNlgyOiEQvF2=M{T6fnNCVkeHUh?=
DELNYrPSIF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXjTb2w5UUN3ME2wMlAzQDF3IN88US=>MYXTRW5ITVJ?
OCI-AML2NF;0[ZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MULJR|UxRTBwMEK4O|Eh|ryPNFzEWJZUSU6JRWK=
LXF-289MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2G4eGlEPTB;MD6wNlg4OiEQvF2=NUDLTW9HW0GQR1XS
IA-LMMWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3GyUmlEPTB;MD6wNlkyPyEQvF2=NGjiXIxUSU6JRWK=
EoL-1-cellM{TWdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnzmTWM2OD1yLkCyPVk3KM7:TR?=NGmyeZRUSU6JRWK=
OVCAR-4M3nDSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlzGTWM2OD1yLkCzNFk1KM7:TR?=MUXTRW5ITVJ?
ES1NF\GVVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2\lN2lEPTB;MD6wN|A6PyEQvF2=NIPlR3VUSU6JRWK=
CESSM4PvSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXzRWlFsUUN3ME2wMlA{ODl7IN88US=>M2XY[XNCVkeHUh?=
GAKNWjq[FJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MknzTWM2OD1yLkCzNVg3KM7:TR?=MY\TRW5ITVJ?
NTERA-S-cl-D1NHjTd4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYnJR|UxRTBwMEOyNlYh|ryPM4HQWnNCVkeHUh?=
TE-10NEL1PYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVLxT3RFUUN3ME2wMlA{OzFzIN88US=>M2HaXHNCVkeHUh?=
CCRF-CEMM2jXdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGf5OGVKSzVyPUCuNFM{PzFizszNMorzV2FPT0WU
NMC-G1MnPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWPNRpd2UUN3ME2wMlA{PDR6IN88US=>M3[1VHNCVkeHUh?=
HOP-62M3\EUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYHhcW0{UUN3ME2wMlA{PTV4IN88US=>M2XtWXNCVkeHUh?=
SH-4M2roRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUPJR|UxRTBwMEO1PFIh|ryPNYj6ZXpZW0GQR1XS
NCI-H1648NGXGUG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnTTTWM2OD1yLkCzOlIzKM7:TR?=MonPV2FPT0WU
EB-3NIDYdpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGDL[I1KSzVyPUCuNFM3PDNizszNM3fBXnNCVkeHUh?=
BB65-RCCMXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnrjTWM2OD1yLkCzOlkyKM7:TR?=MmnoV2FPT0WU
BE-13NWrEbIgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlfLTWM2OD1yLkCzO|U6KM7:TR?=MWLTRW5ITVJ?
CP67-MELMVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NELCO5RKSzVyPUCuNFM4PTlizszNNHvae|VUSU6JRWK=
SW954MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1fuZ2lEPTB;MD6wN|c6KM7:TR?=MUXTRW5ITVJ?
TE-5MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYHJR|UxRTBwMEO4OVQh|ryPM2HZfHNCVkeHUh?=
HCE-4NYC3TYUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1qyTWlEPTB;MD6wN|g2PSEQvF2=M1XpN3NCVkeHUh?=
LC-1FM2TYVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MofGTWM2OD1yLkCzPVg6KM7:TR?=M4T6VnNCVkeHUh?=
TK10NHixRZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXTJR|UxRTBwMESwNVkh|ryPMnzjV2FPT0WU
SJSA-1NEHFcXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH\sXWhKSzVyPUCuNFQyQDhizszNMV\TRW5ITVJ?
DaudiMkXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV7Sd2hGUUN3ME2wMlA1OjJ3IN88US=>NXTkU4I4W0GQR1XS
SW982NXL6O3dXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYjEUnZtUUN3ME2wMlA1OjR4IN88US=>MkTJV2FPT0WU
SF126NV7QcJRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYrJR|UxRTBwMESzOlEh|ryPNU[5U3QzW0GQR1XS
TE-15NGnlNGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIXsWYFKSzVyPUCuNFQ1OzVizszNM2P3bHNCVkeHUh?=
COLO-684MoToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWrJR|UxRTBwMES1OlEh|ryPNXWwNXZQW0GQR1XS
8-MG-BANVzSPZNRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX;JR|UxRTBwMES2Nlkh|ryPNFfjOoFUSU6JRWK=
NB13Mly1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn7oTWM2OD1yLkC0O|c3KM7:TR?=NYLmfJB1W0GQR1XS
HCC1599M1TEeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIj6NFhKSzVyPUCuNFQ5PzlizszNNUTGXHllW0GQR1XS
SK-PN-DWNX\zR3BOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUfJR|UxRTBwMES5OFkh|ryPNXS0[|BbW0GQR1XS
ALL-PONUD3[nZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3XvUmlEPTB;MD6wOFk2PiEQvF2=MoPKV2FPT0WU
NB6NGDLbWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NELyVppKSzVyPUCuNFUzPzFizszNMmnyV2FPT0WU
IST-SL2MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2Pi[WlEPTB;MD6wOVM3OiEQvF2=Mn\yV2FPT0WU
BB30-HNCMkG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX7JR|UxRTBwMEW3N{DPxE1?MXHTRW5ITVJ?
SW962M1;VOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYLXdG54UUN3ME2wMlA2PzZ|IN88US=>Mn7jV2FPT0WU
TGBC24TKBNH\tZ5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUfJR|UxRTBwMEW3PVkh|ryPNGnre4hUSU6JRWK=
KINGS-1NUe1NVh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4jQWGlEPTB;MD6wOVgxOyEQvF2=MlTjV2FPT0WU
HC-1MoOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXXnbmVkUUN3ME2wMlA2QDJ5IN88US=>M2LHVHNCVkeHUh?=
RS4-11NX\wd3o5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1nGNmlEPTB;MD6wOVk{QCEQvF2=NUDGN|ZFW0GQR1XS
LS-123M1i0fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mkf5TWM2OD1yLkC1PVQzKM7:TR?=M2Pnb3NCVkeHUh?=
A3-KAWM1nQcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYi4NYRWUUN3ME2wMlA3OjJ3IN88US=>NF63UY1USU6JRWK=
SNB75M3exTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYLKdZpuUUN3ME2wMlA3OzRzIN88US=>NFK4OXlUSU6JRWK=
SRMXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVPze45rUUN3ME2wMlA3Ozd2IN88US=>MWjTRW5ITVJ?
LOUCYMnrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MW\JR|UxRTBwME[zPVQh|ryPNVP6NI1QW0GQR1XS
K5MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVzGcmdnUUN3ME2wMlA3PDB|IN88US=>NFu5fY9USU6JRWK=
BeckerMUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVXJR|UxRTBwME[0NkDPxE1?M2Lsc3NCVkeHUh?=
CTV-1NYDRcVlrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVvl[|QxUUN3ME2wMlA3PTR6IN88US=>Mn3pV2FPT0WU
KLEMlu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWTJR|UxRTBwME[1PFQh|ryPMVLTRW5ITVJ?
MZ1-PCM33IVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{TQfWlEPTB;MD6wOlU6QCEQvF2=NFnTdGVUSU6JRWK=
MOLT-4M3PSe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MorvTWM2OD1yLkC2OlA2KM7:TR?=NX;DO4JuW0GQR1XS
MLMAMkjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUe0OVNrUUN3ME2wMlA3PzhizszNNFnwZ3pUSU6JRWK=
A388NELNcHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUHJR|UxRTBwME[4PVMh|ryPM1[4bXNCVkeHUh?=
MV-4-11MlXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1ftRWlEPTB;MD6wOlk6PSEQvF2=MXzTRW5ITVJ?
DSH1NU\5Z2dRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYPYd4RTUUN3ME2wMlA4OTd|IN88US=>MV;TRW5ITVJ?
MONO-MAC-6NX3wdFhmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{DZcGlEPTB;MD6wO|IyOiEQvF2=NFfxWXdUSU6JRWK=
ARH-77M1XrfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUPJR|UxRTBwMEeyO|gh|ryPNWLnRms1W0GQR1XS
LB771-HNCNWH5SWduT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVHJR|UxRTBwMEe1OFkh|ryPNITyflJUSU6JRWK=
PF-382NGPHdFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1nhfmlEPTB;MD6wO|U3QSEQvF2=M2TyOnNCVkeHUh?=
KM12NX7Beo9QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4jUfmlEPTB;MD6wO|Y1KM7:TR?=M13UVXNCVkeHUh?=
HAL-01MoD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYrJR|UxRTBwMEe2OVgh|ryPM1zVbXNCVkeHUh?=
RPMI-8402NX75V446T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYT6O|NpUUN3ME2wMlA4Pzh7IN88US=>NGTXWHRUSU6JRWK=
OMC-1M1\s[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1HZVmlEPTB;MD6wO|gxPCEQvF2=MlrSV2FPT0WU
HTMUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHOy[HFKSzVyPUCuNFgh|ryPMUnTRW5ITVJ?
QIMR-WILNEj2[llIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYTJR|UxRTBwMEiwOVUh|ryPMVfTRW5ITVJ?
KNS-42NXLxcW11T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NG\iW3VKSzVyPUCuNFgzODNizszNM37DfXNCVkeHUh?=
BC-3MmXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4PG[2lEPTB;MD6wPFIxPCEQvF2=MmjlV2FPT0WU
ES4MmfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1ryb2lEPTB;MD6wPFI6PiEQvF2=MlnPV2FPT0WU
NCI-H23MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVXk[5ZNUUN3ME2wMlA5PDRizszNMWTTRW5ITVJ?
LB2518-MELNIDOUFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX;JR|UxRTBwMEi2PVYh|ryPMkTLV2FPT0WU
LC4-1NYrqcFQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYraTG5WUUN3ME2wMlA5PzN6IN88US=>NV[yZpA1W0GQR1XS
SIG-M5M{HpUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlL3TWM2OD1yLkC4PVA1KM7:TR?=NVLn[nFUW0GQR1XS
LP-1MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoS2TWM2OD1yLkC4PVM5KM7:TR?=NH3FT|BUSU6JRWK=
TE-8MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYfJR|UxRTBwMEmwNVYh|ryPMXTTRW5ITVJ?
K-562MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXKwR2gyUUN3ME2wMlA6OTJizszNMU\TRW5ITVJ?
J-RT3-T3-5NFLoPYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUHUR29kUUN3ME2wMlA6OTV|IN88US=>NEXYZWRUSU6JRWK=
DU-4475NYLCdpZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MojZTWM2OD1yLkC5NVY2KM7:TR?=MmrvV2FPT0WU
RXF393NF36OFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlTkTWM2OD1yLkC5OFYzKM7:TR?=NIGycldUSU6JRWK=
NB5NWX3XYlET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHjyfY1KSzVyPUCuNFk3OjVizszNMkiwV2FPT0WU
A704M3e1e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlPxTWM2OD1yLkC5O|QyKM7:TR?=MoL3V2FPT0WU
SF268M4Tqfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2W1VGlEPTB;MD6wPVgzPSEQvF2=MmjJV2FPT0WU
UACC-257MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MknrTWM2OD1yLkC5PFM{KM7:TR?=NFO1NodUSU6JRWK=
L-428MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVzQTVA5UUN3ME2wMlExOzJizszNMlPFV2FPT0WU
ST486M3zOfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXvJR|UxRTBwMUC2NFYh|ryPNWHCXZUxW0GQR1XS
SK-MM-2NFznZVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NETJWY1KSzVyPUCuNVA4ODlizszNMWLTRW5ITVJ?
COR-L279Mn\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4DBNWlEPTB;MD6xNFg{OiEQvF2=MnzhV2FPT0WU
JiyoyeP-2003Mo\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF33[41KSzVyPUCuNVA5PDNizszNMmTCV2FPT0WU
GT3TKBMYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIPjO|lKSzVyPUCuNVA6OThizszNMon6V2FPT0WU
HCE-TNFzzb5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV7sfWRLUUN3ME2wMlExQTRizszNMnfwV2FPT0WU
SBC-1M3nU[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVP4XFlCUUN3ME2wMlEyOTF7IN88US=>M4raWnNCVkeHUh?=
KNS-81-FDMWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mmr5TWM2OD1yLkGxNlc{KM7:TR?=MYDTRW5ITVJ?
NCI-H2126NY\Sb3JqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1fkZmlEPTB;MD6xNVM6PCEQvF2=MVHTRW5ITVJ?
EM-2M2jLW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4mySmlEPTB;MD6xNVUzQSEQvF2=M2fEcXNCVkeHUh?=
JARNUPqemF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXnJR|UxRTBwMUG1PVgh|ryPMVTTRW5ITVJ?
NB17MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXHJR|UxRTBwMUG2OVIh|ryPNGWweYZUSU6JRWK=
LB647-SCLCM{\4fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUnJR|UxRTBwMUG3NFUh|ryPNHXIe5RUSU6JRWK=
CAL-148M4nyPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoK3TWM2OD1yLkGxPEDPxE1?NYHwWJFnW0GQR1XS
K052M{O4dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV:2dZJbUUN3ME2wMlEyQDVzIN88US=>M4W1e3NCVkeHUh?=
KARPAS-299MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2POT2lEPTB;MD6xNlI{OyEQvF2=Mm\TV2FPT0WU
KARPAS-422MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3\ad2lEPTB;MD6xNlQ{OiEQvF2=M3vFNnNCVkeHUh?=
LOXIMVIM13iOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYXoWGdYUUN3ME2wMlEzPTF3IN88US=>MofZV2FPT0WU
SCC-3MnK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYfJR|UxRTBwMUK4OVEh|ryPMXvTRW5ITVJ?
LU-139MkO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHfrWlNKSzVyPUCuNVI6PzVizszNNUDiV4hzW0GQR1XS
COLO-320-HSRMn65S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYnJT|JbUUN3ME2wMlE{ODh4IN88US=>NYPTT|J{W0GQR1XS
ONS-76NXzrVHdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlzBTWM2OD1yLkGzNVMh|ryPNH3xV|dUSU6JRWK=
U-266MmTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUDJR|UxRTBwMUOyOFUh|ryPNXLPOpdGW0GQR1XS
HHMmr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXPqdohUUUN3ME2wMlE{PTN3IN88US=>M{TTb3NCVkeHUh?=
BB49-HNCMU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV;JR|UxRTBwMUO1PFch|ryPMkG1V2FPT0WU
NCI-SNU-5MnnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1mweGlEPTB;MD6xN|U6PiEQvF2=NVS3eVNiW0GQR1XS
C2BBe1NUH3dHMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MljvTWM2OD1yLkGzO|Q3KM7:TR?=NGW2NoFUSU6JRWK=
ML-2NGnXT|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXn4TJlkUUN3ME2wMlE{QTV|IN88US=>NEX3R3VUSU6JRWK=
SCHM1nON2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWDJR|UxRTBwMUO5O|Qh|ryPNIjUSWxUSU6JRWK=
NCI-H82NXe1e|QyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NG\HXpdKSzVyPUCuNVQyODRizszNMXLTRW5ITVJ?
MDA-MB-134-VINX2yW5M2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYi4dJR1UUN3ME2wMlE1OjV{IN88US=>MYLTRW5ITVJ?
SK-N-DZNVv6XJVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlHnTWM2OD1yLkG0O|E6KM7:TR?=NX34OIp7W0GQR1XS
HL-60NI[yZYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUjJR|UxRTBwMUS5NkDPxE1?MVTTRW5ITVJ?
LB373-MEL-DMmmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVvkUVhGUUN3ME2wMlE2PTN7IN88US=>NFjjZ3hUSU6JRWK=
LB831-BLCNEfCRmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MljsTWM2OD1yLkG2NFc3KM7:TR?=MWTTRW5ITVJ?
SK-NEP-1MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mk\lTWM2OD1yLkG2NVAyKM7:TR?=NVuzPHFRW0GQR1XS
IMR-5NF7lV3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUP2WlJ1UUN3ME2wMlE3PDh|IN88US=>MYDTRW5ITVJ?
Calu-6M1fGNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUDJR|UxRTBwMU[1N|ch|ryPMl;1V2FPT0WU
NCI-H1882MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NInBO|FKSzVyPUCuNVY4OjhizszNMUHTRW5ITVJ?
NCI-H446MnfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV7JR|UxRTBwMU[4PVEh|ryPM3vwZ3NCVkeHUh?=
GI-ME-NM4fwfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MW\JR|UxRTBwMUiwNkDPxE1?MYrTRW5ITVJ?
MPP-89Mo\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV3kXI5XUUN3ME2wMlE5OTJzIN88US=>NVvEdGN2W0GQR1XS
CGTH-W-1NVHlXYpPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIPYU5RKSzVyPUCuNVg1OzZizszNNFT6VmZUSU6JRWK=
MEG-01NGfUbFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnXYTWM2OD1yLkG4OlI5KM7:TR?=M3:wb3NCVkeHUh?=
NCI-H748M1v5eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEnN[JNKSzVyPUCuNVg6OTFizszNNGTwdHZUSU6JRWK=
COLO-829M2fwdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MU\JR|UxRTBwMkC2O|Mh|ryPMkniV2FPT0WU
GOTONYe1XIVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkiyTWM2OD1yLkKwO|Mh|ryPMl3JV2FPT0WU
EW-3M1zLXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXrJR|UxRTBwMkG3NVgh|ryPMUDTRW5ITVJ?
KY821M3q5T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoD2TWM2OD1yLkKyNFQ2KM7:TR?=MYnTRW5ITVJ?
CTB-1M2fiUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYOyW|RVUUN3ME2wMlIzOjJ6IN88US=>MmXwV2FPT0WU
TALL-1NHP2UIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWnJR|UxRTBwMkK5NlEh|ryPMlezV2FPT0WU
NCI-H209M{TCO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{LXfWlEPTB;MD6yNlk3OiEQvF2=MoGyV2FPT0WU
IST-MES1MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NE\jRm1KSzVyPUCuNlM2OSEQvF2=MXjTRW5ITVJ?
DMS-114MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWXJR|UxRTBwMkO5PVMh|ryPNXXiXFl2W0GQR1XS
SNU-C2BNWXDR3JUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkjKTWM2OD1yLkK0N|E3KM7:TR?=MYjTRW5ITVJ?
DG-75M3\NTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXHJR|UxRTBwMk[xPVUh|ryPNFezSXdUSU6JRWK=
D-336MGM3jCdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mom5TWM2OD1yLkK2OVU4KM7:TR?=M3u4dnNCVkeHUh?=
KMOE-2M2PQemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWLJR|UxRTBwMke1N|gh|ryPM33qbXNCVkeHUh?=
NB1M1XhN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4LufmlEPTB;MD6yO|kzPiEQvF2=M2jqOnNCVkeHUh?=
RH-1NFHydYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{PYOWlEPTB;MD6yO|k5QSEQvF2=M{LvNHNCVkeHUh?=
TE-1MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2jjSGlEPTB;MD6yPFQ4QSEQvF2=MmK0V2FPT0WU
RPMI-6666MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXzJR|UxRTBwMki4OEDPxE1?MYDTRW5ITVJ?
TE-9MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYH4R|hSUUN3ME2wMlI5QTh3IN88US=>NGjBXWRUSU6JRWK=
BT-474MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWrJR|UxRTBwMkmzN|Qh|ryPNHnZOJVUSU6JRWK=
COLO-668M3PWemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIXQWo5KSzVyPUCuNlk1OjlizszNNF\IUpFUSU6JRWK=
NCI-H1581MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHXKe2NKSzVyPUCuNlk3QDlizszNNFLrRVRUSU6JRWK=
MN-60NXXy[5p{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYfxe2xxUUN3ME2wMlI6QTB3IN88US=>MWDTRW5ITVJ?
L-540NFjERXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3X0SGlEPTB;MD6zNFA5OSEQvF2=MUDTRW5ITVJ?
MOLT-13NWrBcXRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYDyUopXUUN3ME2wMlMxOTh|IN88US=>Mmf6V2FPT0WU
NCI-SNU-16NWP0Vm94T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MofOTWM2OD1yLkOwNlA2KM7:TR?=MWHTRW5ITVJ?
NCI-H64NFPU[ZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF:yTJpKSzVyPUCuN|A{OzFizszNNUPBTpVuW0GQR1XS
CP66-MELNFTGSoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXfY[WViUUN3ME2wMlMyPDF3IN88US=>M3rrS3NCVkeHUh?=
NB69MnvKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXLJR|UxRTBwM{KxPFgh|ryPNILVN5ZUSU6JRWK=
NCI-H2196MleyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXjJR|UxRTBwM{OwN|Yh|ryPM3nhbnNCVkeHUh?=
MHH-CALL-2MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkDCTWM2OD1yLkOzOFY5KM7:TR?=NXXicYZSW0GQR1XS
HCC2157MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXjOW5Y3UUN3ME2wMlM{QTV2IN88US=>M{izPXNCVkeHUh?=
LS-1034NHL5WXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4DPXmlEPTB;MD6zOlM5QCEQvF2=NFHpZXdUSU6JRWK=
BOKUM3XpTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3fUVGlEPTB;MD6zO|E6QSEQvF2=MorRV2FPT0WU
GDM-1M3rnPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlO3TWM2OD1yLkO3NlM1KM7:TR?=MXfTRW5ITVJ?
TGWMX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoTrTWM2OD1yLkO3OFU{KM7:TR?=MmTCV2FPT0WU
SNU-C1NV3QR2hrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnrhTWM2OD1yLkO4NlE2KM7:TR?=MljYV2FPT0WU
LS-513MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnHiTWM2OD1yLkO5NFcyKM7:TR?=NF3XfnBUSU6JRWK=
NOMO-1NYPCXpBXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXnScoRPUUN3ME2wMlM6QTdzIN88US=>NH30dIVUSU6JRWK=
MS-1NVi4R5FET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml7jTWM2OD1yLkSwNVc4KM7:TR?=NX\PcY1qW0GQR1XS
EKVXMnLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4rxUWlEPTB;MD60OFQ3OSEQvF2=MVzTRW5ITVJ?
SK-MEL-2MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFqwV3ZKSzVyPUCuOFY1KM7:TR?=MmmyV2FPT0WU
HCC1187MlWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXHHS4ROUUN3ME2wMlQ3PzZ6IN88US=>MX3TRW5ITVJ?
HCC2218NEnuS4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnXrTWM2OD1yLkS3NlI4KM7:TR?=NF7jUo5USU6JRWK=
NCI-H187NFy2cYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmT3TWM2OD1yLkS3PFQh|ryPNWnvPYlIW0GQR1XS
DBMlXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4HYNmlEPTB;MD61NFA2PSEQvF2=NIXRTW9USU6JRWK=
NCI-H69NIPPUoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkDyTWM2OD1yLkWwNlQ4KM7:TR?=Mn;qV2FPT0WU
NCI-H1694MmexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmqwTWM2OD1yLkWwOlk4KM7:TR?=M2i2PHNCVkeHUh?=
CA46MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4S4cmlEPTB;MD61NFkyPyEQvF2=MVjTRW5ITVJ?
EHEBMXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3TK[mlEPTB;MD61NVE6OyEQvF2=M{n0RXNCVkeHUh?=
NCCITM3O4NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIf6bndKSzVyPUCuOVQ{OjFizszNNIWyRVFUSU6JRWK=
NCI-H720MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXLJR|UxRTBwNUS5OlIh|ryPM1LqdHNCVkeHUh?=
LU-134-AM3jkfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVnJR|UxRTBwNUWyPVYh|ryPMmnTV2FPT0WU
MC-CARMnrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH;BXVRKSzVyPUCuOVU1OzFizszNNIDQVVZUSU6JRWK=
NEC8NUG3[YN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWTJR|UxRTBwNU[xO|Ih|ryPNUHMT|EzW0GQR1XS
NCI-H524NIP0fVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX30XmIzUUN3ME2wMlU5PzR6IN88US=>NUPZZlRvW0GQR1XS
NCI-H1963MnfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{fMZWlEPTB;MD62NlU5KM7:TR?=NHf2V2hUSU6JRWK=
SU-DHL-1NIXFUGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEjPcFlKSzVyPUCuOlQ2OjZizszNNGL5bo1USU6JRWK=
NCI-H1522Mom5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnvtTWM2OD1yLk[0PFg{KM7:TR?=M{n6c3NCVkeHUh?=
NCI-H1155NH;ETnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NETjTZBKSzVyPUCuOlU{PSEQvF2=M4fzcHNCVkeHUh?=
D-263MGNHrPVlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVn0e4l[UUN3ME2wMlY3OTBzIN88US=>NXTxWJFmW0GQR1XS
TE-6NH7wN3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{iyfGlEPTB;MD62PFExPCEQvF2=M{DrbHNCVkeHUh?=
NCI-H1417MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2\RemlEPTB;MD62PVcyOSEQvF2=M4\ZR3NCVkeHUh?=
NCI-H510ANUTOeVEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoHJTWM2OD1yLke3NlM3KM7:TR?=M3\EUXNCVkeHUh?=
KARPAS-45NUT1UmlUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlX2TWM2OD1yLke4NlM2KM7:TR?=MYjTRW5ITVJ?
IST-SL1MmfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXrZWFZ7UUN3ME2wMlg2QDJ3IN88US=>NGTXe5FUSU6JRWK=
COLO-824MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXHJR|UxRTBwOEe4N|Uh|ryPNH\GWJpUSU6JRWK=
NCI-H526NWXTcpVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYfPUVM6UUN3ME2wMlkxQTV6IN88US=>M372ZnNCVkeHUh?=
NCI-H719NWj6SIdET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWDJR|UxRTBwOU[2OVch|ryPMl\FV2FPT0WU
SF539NFO0UnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVTJR|UxRTBwOUizPVYh|ryPMo[5V2FPT0WU
NKM-1NIW0[ZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYHH[|ZuUUN3ME2wMlk5PjZ|IN88US=>MkC1V2FPT0WU
A253NIPhSJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnfMTWM2OD1yLkm4PFg2KM7:TR?=NWDSZZliW0GQR1XS
TE-441-TM4nMfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGmwUGRKSzVyPUGuNFQ{PSEQvF2=NUDh[oVWW0GQR1XS
COR-L88M4rvPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFfyXXJKSzVyPUGuNVE{PTRizszNNFLuc2lUSU6JRWK=
CPC-NNG[yb2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFHtN3hKSzVyPUGuNVU5QDhizszNMli4V2FPT0WU
NCI-H2107MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV\6UXBRUUN3ME2xMlE4OjZzIN88US=>MljBV2FPT0WU
ECC4M2XBcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2DT[2lEPTB;MT6xPFY6OyEQvF2=MXLTRW5ITVJ?
NCI-H2141NG\MfYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXf0RndrUUN3ME2xMlE6Ojl7IN88US=>NX;2XIZyW0GQR1XS
NCI-H1770MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3TjUmlEPTB;MT6zNlkzQCEQvF2=NV\OepBpW0GQR1XS
NCI-SNU-1MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFXHdHZKSzVyPUGuN|MxPCEQvF2=NILqT5BUSU6JRWK=
LU-165NHmwfZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYLEWoxQUUN3ME2xMlQ2PDZ5IN88US=>Ml3wV2FPT0WU
RajiNVHxc3pMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGHzZmtKSzVyPUGuOFczPTlizszNM4O2bnNCVkeHUh?=
EW-24NFLSRXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGOxem9KSzVyPUGuOVQ3OTlizszNNIWwbW9USU6JRWK=
KP-N-RT-BM-1MlHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkS4TWM2OD1zLkW2OVUyKM7:TR?=M4LKOXNCVkeHUh?=
SK-MEL-1MlHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX3JR|UxRTFwNkS4O|ch|ryPMor0V2FPT0WU
SCLC-21HNIHRV3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYe2XmJFUUN3ME2xMlY3PjVzIN88US=>M2j2OnNCVkeHUh?=
SIMANFzkTHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWn1[Ih5UUN3ME2xMlY5OjN|IN88US=>Mm\RV2FPT0WU
NCI-H1304NEf1fYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF3ueZFKSzVyPUGuO|A4PjVizszNNIjHSlZUSU6JRWK=
REHNIi0doxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVP2NFNNUUN3ME2xMlcyODd6IN88US=>MnftV2FPT0WU
KP-N-YSNGrlbWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXrJR|UxRTFwOUO1OVEh|ryPMlTuV2FPT0WU
DMS-153M4fwWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEDtV4VKSzVyPUGuPVc2QSEQvF2=NF7J[GdUSU6JRWK=
NB10NYDFTIE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGrtfm5KSzVyPUKuNlA5PzhizszNNEG1S2hUSU6JRWK=
NCI-H345MnfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NInJPVFKSzVyPUKuOlE6ODVizszNMnfjV2FPT0WU
SK-N-FIMXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUXJR|UxRTJwN{WzPFEh|ryPNInQOpZUSU6JRWK=
NCI-H1092M4PMR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{TUZ2lEPTB;Mj65OVM6PCEQvF2=NYnodlV1W0GQR1XS
KM-H2NX22W414T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{DhfWlEPTB;Mz62OVM6PiEQvF2=NHixXoZUSU6JRWK=
KG-1NG\ZV45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGHrbnZKSzVyPUOuO|E3QDhizszNNFTLRVZUSU6JRWK=
D-283MEDMV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4XkeWlEPTB;Mz63OVg4KM7:TR?=MWrTRW5ITVJ?
LU-65M3e1emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFnRUItKSzVyPUSuNVE1QDVizszNMo\WV2FPT0WU
MSTO-211HM3rHU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWnJR|UxRTRwMUi4PVgh|ryPNYLlcVRsW0GQR1XS
NCI-H2081MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlL2TWM2OD12LkK5NVc1KM7:TR?=MWDTRW5ITVJ?
D-247MGNX23WIhrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkHFTWM2OD12LkSzNVkyKM7:TR?=M3G0UHNCVkeHUh?=
P31-FUJMVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmPUTWM2OD12LkS1NFE6KM7:TR?=M{jNfHNCVkeHUh?=
DMS-79NYLkO402T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3P4V2lEPTB;ND65N|E5OyEQvF2=M{Lo[3NCVkeHUh?=
KASUMI-1M1n1UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFztOJdKSzVyPUSuPVc2ODlizszNMVTTRW5ITVJ?
JVM-3NWWzRWpFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1PIc2lEPTB;NT6yOVAyPCEQvF2=Moj4V2FPT0WU
LAN-6Ml3XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml3kTWM2OD13LkWxO|M3KM7:TR?=NETCeVlUSU6JRWK=
DJM-1MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFPEd4lKSzVyPUWuOVYxOjlizszNMUDTRW5ITVJ?
JVM-2NFrQRY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFLuOlVKSzVyPUWuOlcxQTJizszNNFrvRXVUSU6JRWK=
U-87-MGMkH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NU\JSnlJUUN3ME21Mlg6QTZ2IN88US=>NEDOU4hUSU6JRWK=
SHP-77NYm2VGJkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF;oV4tKSzVyPUWuPVQ6OjhizszNNIPkeolUSU6JRWK=
RPMI-8866MoDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1TXVGlEPTB;Nj6yO|AyOyEQvF2=NIrQV2xUSU6JRWK=
ES7M1Tm[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHXHcIxKSzVyPU[uN|k6OjRizszNMYrTRW5ITVJ?
WSU-NHLNF65dYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NULwb5FuUUN3ME22MlUyPjB7IN88US=>MYXTRW5ITVJ?
CAS-1MljXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnTWTWM2OD15LkC5O|Q6KM7:TR?=NG\1e|JUSU6JRWK=
MHH-NB-11NIXpRoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXLMTXY2UUN3ME24MlI{OTV{IN88US=>MnjQV2FPT0WU
ES5NEHxc|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWq1[ZdYUUN3ME25MlUzOjh4IN88US=>NYDHXZpkW0GQR1XS
HDLM-2MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYG3N296UUN3ME25Mlk2QTB{IN88US=>Mle0V2FPT0WU
NCI-H2171MlvwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHG0NG5KSzVyPUGwMlU6OjdizszNNEHmd4xUSU6JRWK=
LNCaP-Clone-FGCMYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoLDTWM2OD1zMT6zO|E5KM7:TR?=M1XtbHNCVkeHUh?=
NCI-H1395NH:zZnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4roUWlEPTB;MUKuNlY6QSEQvF2=MYrTRW5ITVJ?
NCI-H1436M1;SW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXHJR|UxRTF|LkOxPVUh|ryPNGnTVYhUSU6JRWK=
RCC10RGBMoH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFPESnJKSzVyPUGzMlMzOjFizszNNUTlVYlbW0GQR1XS
SW684MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWDWVlJ3UUN3ME2xN{46Pzl5IN88US=>MYTTRW5ITVJ?
NCI-H1650NUjxdIxLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF3q[ldKSzVyPUG1MlA1PDdizszNM{jXXXNCVkeHUh?=
EW-13MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX3JR|UxRTF3LkKwNlEh|ryPM1W4b3NCVkeHUh?=
EC-GI-10MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFf2fllKSzVyPUG1Mlg3PDRizszNMXjTRW5ITVJ?
CHP-126NXfDNVRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml3xTWM2OD1zNz6xPVE5KM7:TR?=MWHTRW5ITVJ?
NCI-H226MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYjJR|UxRTF6LkC0NFMh|ryPNImwXYtUSU6JRWK=
NCI-H1838M3vncmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkLjTWM2OD1{MD6xPFQ5KM7:TR?=MkTYV2FPT0WU
EW-11MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlfTTWM2OD1{ND6yO|E5KM7:TR?=MX7TRW5ITVJ?
EB2MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M13rNWlEPTB;M{GuOVMyQCEQvF2=MVjTRW5ITVJ?
D-502MGM3\qPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXnUflc1UUN3ME20N{46OjJ7IN88US=>MWLTRW5ITVJ?
U-698-MM4XYTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX[xUFlSUUN3ME20PE45PjdzIN88US=>NGX4NppUSU6JRWK=
ES3M4T1cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYezWnFPUUN3ME20PU4{QDl|IN88US=>NFWzW4RUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Torin1 is efficacious at a dose of 20 mg/kg in a U87MG xenograft model and demonstrates good pharmacodynamic inhibition of downstream effectors of mTOR in tumor and peripheral tissues. [2]
Features

Protocol(Only for Reference)

Kinase Assay: [1]

mTORC1 and mTORC2 in Vitro Kinase Assays To produce soluble mTORC1, HEK-293T cell lines that stably express N-terminally FLAG-tagged Raptor are generated using vesicular stomatitis virus G-pseudotyped MSCV retrovirus. For mTORC2, similar HeLa cells that stably express N-terminally FLAG-tagged Protor-1 are generated. Both complexes are purified by lysing cells in 50 mm HEPES, pH 7.4, 10 mm sodium pyrophosphate, 10 mm sodium β-glycerophosphate, 100 mm NaCl, 2 mm EDTA, 0.3% CHAPS. Cells are lysed at 4 °C for 30 min, and the insoluble fraction is removed by microcentrifugation at 13,000 rpm for 10 min. Supernatants are incubated with FLAG-M2 monoclonal antibody-agarose for 1 h and then washed three times with lysis buffer and once with lysis buffer containing a final concentration of 0.5 M NaCl. Purified mTORC1 is eluted with 100 μg/mL 3×FLAG peptide in 50 mm HEPES, pH 7.4, 100 mm NaCl. Eluate can be aliquoted and stored at -80 °C. Substrates S6K1 and Akt1 are purified. Kinase assays are performed for 20 min at 30 °C in a final volume of 20 μL consisting of the kinase buffer (25 mm HEPES, pH 7.4, 50 mm KCl, 10 mm MgCl2, 500 μm ATP) and 150 ng of inactive S6K1 or Akt1 as substrates. Reactions are stopped by the addition of 80 μL of sample buffer and boiled for 5 min. Samples are subsequently analyzed by SDS-PAGE and immunoblotting.

Cell Assay: [1]

Cell lines MEFs
Concentrations ~250 nM
Incubation Time 4 days
Method Cell viability is assessed with the CellTiter-Glo Luminescent Cell Viability Assay. On Day 0, 96-well plates are seeded with 500 cells per well and grown overnight. On Day 1, cells are treated with the appropriate compounds and subsequently analyzed on Days 3-5. For analysis, plates are incubated for 60 min at room temperature; 50 μL of CellTiter-Glo reagent is added to each well, and plates are mixed on an orbital shaker for 12 min. Luminescence is quantified on a standard plate luminometer.

Animal Study: [2]

Animal Models U87MG xenograft model
Formulation Torin1 powder is first dissolved at 25 mg/mL in 100% N-methyl-2-pyrrolidone and subsequently diluted 1:4 with sterile 50% PEG400 to a final concentration of 5 mg/mL
Dosages 20 mg/kg
Administration Administered via i.p. once daily

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Thoreen CC, et al, J Biol Chem, 2009, 284(12), 8023-8032.

[2] Liu Q, et al, J Med Chem, 2010, 53(19), 7146-7155.

view more

Chemical Information

Download Torin 1 SDF
Molecular Weight (MW) 607.62
Formula

C35H28F3N5O2

CAS No. 1222998-36-8
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 2 mg/mL (3.29 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 30% PEG 400+0.5% Tween80+5% Propylene glycol 30mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name Benzo[h]-1,6-naphthyridin-2(1H)-one, 1-[4-[4-(1-oxopropyl)-1-piperazinyl]-3-(trifluoromethyl)phenyl]-9-(3-quinolinyl)-

Frequently Asked Questions

  • Question 1
    How to re-constitute the inhibitor for i.p. administration?

    Answer: S2827 Torin 1 can be dissolved in 5% DMSO/30% PEG 300/ddH2O at 0.25 mg/ml clearly, and in 10% DMSO/corn oil at 0.5 mg/ml, it is also a clear solution.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related mTOR Products

  • MHY1485

    MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.

  • CHIR-99021 (CT99021)

    CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively.

  • Dorsomorphin

    Dorsomorphin is a potent, reversible, selective AMPK inhibitor with Ki of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Also inhibits type I BMP receptor activity.

  • Rapamycin (Sirolimus)

    Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

  • Everolimus (RAD001)

    Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay.

  • AZD8055

    AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM in MDA-MB-468 cells with excellent selectivity (∼1,000-fold) against PI3K isoforms and ATM/DNA-PK. Phase 1.

    Features:First drug to inhibit both types of mTOR protein.

  • Temsirolimus (CCI-779, NSC 683864)

    Temsirolimus (CCI-779, NSC 683864) is a specific mTOR inhibitor with IC50 of 1.76 μM in a cell-free assay.

  • INK 128 (MLN0128)

    INK 128 (MLN0128) is a potent and selective mTOR inhibitor with IC50 of 1 nM in cell-free assays; >200-fold less potent to class I PI3K isoforms, superior in blocking mTORC1/2 and sensitive to pro-invasion genes (vs Rapamycin). Phase 1.

  • Tacrolimus (FK506)

    Tacrolimus (FK506) is a 23-membered macrolide lactone, it reduces peptidyl-prolyl isomerase activity in T cells by binding to the immunophilin FKBP12 (FK506 binding protein) creating a new complex.

  • KU-0063794

    KU-0063794 is a potent and highly specific dual-mTOR inhibitor of mTORC1 and mTORC2 with IC50 of ~10 nM in cell-free assays; no effect on PI3Ks.

Recently Viewed Items

Tags: buy Torin 1 | Torin 1 supplier | purchase Torin 1 | Torin 1 cost | Torin 1 manufacturer | order Torin 1 | Torin 1 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us